Gyon Technologies Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Gyon Technologies Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,440	Closed	-$388K	–	632
2022 Q3	$388K	Buy	+15,440	New	+$428K	0.12%	170
2022 Q1	–	Sell	-7,765	Closed	-$205K	–	635
2021 Q4	$205K	Buy	7,765 +3,012	+63%	+$233K	0.04%	513
2021 Q3	$478K	Buy	+4,753	New	+$557K	0.13%	207
2021 Q2	–	Sell	-20,288	Closed	-$2.02M	–	520
2021 Q1	$2.02M	Buy	20,288 +8,958	+79%	+$1.04M	0.88%	15
2020 Q4	$1.4M	Buy	+11,330	New	+$1.49M	0.48%	55

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Gyon Technologies Capital Management's RETA Position: Q4 2022 in Review

Gyon Technologies Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 15,440 shares — an estimated $388K sold.

Gyon Technologies Capital Management first reported a position in RETA in Q4 2020 and held it in 5 quarters. The position peaked at $2.02M in Q1 2021. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Gyon Technologies Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 15,440 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $388K.
Gyon Technologies Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 5 quarters.
Gyon Technologies Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.02M in Q1 2021.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.